A Single-arm, Open-label， Phase Ⅱ Clinical Trial of Eutideron, Etoposide Combined With Bevacizumab for Breast Cancer Patients With Brain Metastases
Overview
- Phase
- Not Applicable
- Intervention
- eutidrone etoposide bevacizumab
- Conditions
- Mammary Neoplasms, Human
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Enrollment
- 43
- Locations
- 1
- Primary Endpoint
- CNS Objective response rate (CNS-ORR)
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
This study was a single-arm, open-label, phase II study of breast cancer patients with brain metastases. Eligible patients received a regimen of eutidrone(30mg/m2/d,iv,d1-5,21d/cycle), etoposide(30mg/m2/d,iv,d1-3,21d/cycle), and bevacizumab (10mg/kg,d1,21d/cycle).At least 4 to 6 cycles were administered, and if patients had a response or stable disease, bevacizumab was used as maintenance therapy until disease progression or intolerable toxicity.
Detailed Description
The natural survival time of breast cancer patients with brain metastases is short and the prognosis is poor. Although the treatment is progressing, but it is still limited. The current domestic guidelines still recommend local therapy as a priority treatment strategy. At the same time, about 80% of patients with brain metastasis will progress to extracranial metastasis, so superior systemic treatment is particularly important, but very lacking.Therefore, new systematic therapeutic drugs are urgently needed .Eutiderone is a new generation of epirubicin anti-tumor drug with good efficacy and safety. In pre-clinical studies, it has been shown that the drug concentration in most tissues is higher than that in plasma, and the concentration of eutiderone in brain tissue is higher, indicating that the drug is easy to cross the blood-brain barrier.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Signed informed consent form.
- •Female,\>
- •Histologically or cytologically confirmed recurrent metastatic breast cancer.
- •There was at least one measurable lesion in the central nervous system.
- •Based on screening brain magnetic resonance imaging (MRI), patients with CNS must meet one of the following conditions：
- •Untreated brain metastases from breast cancer do not require immediate local treatment.
- •Previously treated breast cancer brain metastases that have progressed after previous central nervous system local treatment as assessed by the investigator and that do not have clinical features requiring immediate local treatment.
- •Previous anti-HER2 therapy and TKI therapy were required for HER2+ patients.
- •Patients who had not received chemotherapy, radiotherapy, surgery, targeted therapy or immunotherapy within 4 weeks before enrollment.
- •All toxicity in patients associated with previous antitumor therapy must be restored to ≤ grade 1 (CTCAE v5.0). However, patients with any grade of alopecia were allowed.
Exclusion Criteria
- •Other malignant tumors (including primary brain or leptomeningeal related tumors) within the past 5 years, except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix;
- •Previous anti-tumor therapy, including chemotherapy, radical radiotherapy, hormone therapy, biological therapy, immunotherapy or anti-tumor traditional Chinese medicine therapy within 4 weeks before initiation of study treatment.
- •Patients had previously used eutidrone injection, etoposide, or bevacizumab.
- •Patients had undergone major organ surgery (excluding needle biopsies) or major trauma within 4 weeks before the first dose of the study drug, or required elective surgery during the trial.
- •Patients with ≥grade 3 neurosystem-related severe adverse reactions after previous use of anti-microtubules.
- •Patients with any untreated \> 2.0cm brain injury, unless discussed with the investigator and approved for registration.
- •Systemic corticosteroids were continued to control symptoms of brain metastases at a total daily dose of \>2mg dexamethasone (or equivalent). However, patients with chronic stable doses ≤2mg daily of dexamethasone (or equivalent) may be discussed and approved by the investigator.
- •Any brain lesion deemed to require immediate local treatment, including (but not limited ) increased lesion size at anatomical sites or possible treatment-related edema, may pose a risk to the patient (e.g.brain stem lesions). Patients received local treatment were still eligible for study based on lesions identified by screening contrast brain MRI according to the criteria described in the CNS inclusion criteria.
- •More than 2 seizures within 4 weeks before enrollment.
- •Poor control of hypertension; Or a previous history of hypertensive crisis or hypertensive encephalopathy.
Arms & Interventions
eutidrone+ etoposide+ bevacizumab
Eligible patients received a regimen of eutidrone(30mg/m2/d,iv,d1-5,21d/cycle), etoposide(30mg/m2/d,iv,d1-3,21d/cycle), and bevacizumab (10mg/kg,d1,21d/cycle).At least 4 to 6 cycles were administered, and if patients had a response or stable disease, bevacizumab was used as maintenance therapy until disease progression or intolerable toxicity.
Intervention: eutidrone etoposide bevacizumab
Outcomes
Primary Outcomes
CNS Objective response rate (CNS-ORR)
Time Frame: 12 months
The proportion of patients with complete response (CR) and partial response (PR) evaluated as the best response observed from enrollment to progression of all CNS target lesions assessed according to RANO-BM criteria among the total number of patients who could be evaluated.
Secondary Outcomes
- CNS Clinical benefit rate(CNS-CBR)(3 months)
- Objective response rate (ORR)(12 months)
- Progression-free survival（PFS）(36 months)
- CNS Progression-free survival (CNS-PFS)(36 months)
- Overall survival (OS)(36 months)